Eyenovia To Collaborate With SGN Nanopharma To Develop Treatment For Dry Eye Disease

(RTTNews) - Eyenovia, Inc. (EYEN) Thursday announced that it has signed a collaborative agreement with SGN Nanopharma to develop a treatment for chronic dry eye disease.

The companies will work to develop SGN's Micellar Nanoparticle Platform platform-based cyclosporine formulation for use with Eyenovia's Optejet dispenser.

The companies are currently validating the novel drug-device combination product's manufacturability. Further, it will schedule a consultation meeting with the FDA to discuss clinical development.

Michael Rowe, chief executive officer of Eyenovia said, "The Optejet dispenser has been shown in prior studies to deliver a therapeutic dose of medication with 80% less drug volume, thereby minimizing exposure to harmful preservatives and improving tolerability.